Novo Nordisk says obesity drug helps up to 13.8 percent weight loss in phase 2 trial

COPENHAGEN (Reuters) - Danish drugmaker Novo Nordisk said on Friday a phase 2 trial for its big hope in tackling obesity, an improved GLP-1 drug called semaglutide, showed a weight loss of up to 13.8 percent in people with severe conditions.